Ulloa PJJ, Juan LCLE

Language: Spanish
References: 10
Page: 106-111
PDF size: 289.01 Kb.

ABSTRACT

Background: Secondary leukemias are broadly defined as a group of cancers that arise after the existence of a previous malignant neoplasm or in patients previously treated with cytotoxic therapy, that is, chemotherapy or radiotherapy.
Clinical case: A 32-year-old male patient with lymphoblastic lymphoma who received 8 cycles of chemotherapy with subsequent development of secondary acute lymphoblastic leukemia, requiring initiation of a remission induction chemotherapy scheme based on Hyper-CVAD, developing secondary bone marrow aplasia.
Conclusions: Secondary lymphoblastic leukemias are a poorly characterized condition due to limited literature and the absence of therapeutic protocols.

REFERENCES

1. Ferraro F, Gao F, Stockerl-Goldstein K, Westervelt P, DiPersioJF, Ghobadi A. Secondary acute lymphoblastic leukemia,a retrospective analysis from Washington University andmeta-analysis of published data. Leuk Res 2018 ; 72: 86-91.doi: 10.1016/j.leukres.2018.07.024.

2. Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA,Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H,Spielberger R, O'Donnell M, Snyder D, Slavin T, NakamuraR, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Therapyrelatedacute lymphoblastic leukemia has distinct clinicaland cytogenetic features compared to de novo acutelymphoblastic leukemia, but outcomes are comparablein transplanted patients. Haematologica 2018; 103 (10):1662-1668. doi: 10.3324/haematol.2018.193599.

3. Rowe JM. Therapy of secondary leukemia. Leukemia 2002;16 (4): 748-750. doi: 10.1038/sj.leu.2402456.

4. Piszcz J, Bolkun L, Cichocka E, Kloczko J. Secondary acutelymphoblastic leukaemia in a multiple myeloma patient.Contemporary oncology (Poznan, Poland) 2012; 16 (6):

5. 593-595. doi: 10.5114/wo.2012.32497.5. Ganzel C, Devlin S, Douer D, Rowe JM, Stein EM, TallmanMS. Secondary acute lymphoblastic leukaemia is constitutionaland probably not related to prior therapy. Br JHaematology 2015; 170 (1): 50-55. doi: 10.1111/bjh.13386.

6. Cowell IG, Austin CA. Mechanism of generation of therapyrelated leukemia in response to anti-topoisomerase IIagents. Int J Environ Res Public Health 2012; 9 (6): 2075-2091. doi: 10.3390/ijerph9062075.

7. Pagano L, Pulsoni A, Tosti ME, Annino L, et al. Acutelymphoblastic leukaemia occurring as second malignancy:report of the GIMEMA Archive of Adult AcuteLeukaemia. Gruppo Italiano Malattie Ematologiche Malignedell'Adulto. Br J Haematol 2001; 106 (4): 1037-1040.https://doi.org/10.1046/j.1365-2141.1999.01636.x

8. Swaika A, Frank RD, Yang D, Finn L, et al. Second primaryacute lymphoblastic leukemia in adults: a SEER analysis ofincidence and outcomes. Cancer Med 2018; 7 (2): 499-507.doi: 10.1002/cam4.1266.

9. Rosenberg AS, Brunson A, Paulus JK, Tuscano J, et al. Secondaryacute lymphoblastic leukemia is a distinct clinicalentity with prognostic significance. Blood Cancer J 2017;7 (9): e605. doi: 10.1038/bcj.2017.81.

10. Shivakumar R, Tan W, Wilding GE, Wang ES, et al. Biologicfeatures and treatment outcome of secondary acutelymphoblastic leukemia--a review of 101 cases. AnnOncol 2008; 19 (9): 1634-1638. doi: 10.1093/annonc/